$120.94-0.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Company outlook: revenue of $5.1B to $5.3B for Fiscal year 2026 — up 1.0% on a year earlier, slower than the 37.7% just reported
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.6B | $1.4B | +14.00% |
| Profit | -$784.8M | $424.2M | -285.02% |
| Profit per share | -$3.86 | $2.11 | -282.94% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
XR ™ (ruxolitinib) Extended-Release Tablets Jakafi XR ™ (ruxolitinib) extended-release tablets are a once-daily (QD) formulation of ruxolitinib, approved for use in the U.S. for the treatment of PV in adults who have had an inadequate response to, or are intolerant of, hydroxyurea; intermediate or high-risk MF, including primary MF, post-PV MF, and post-essential thrombocythemia MF in adults; steroid-refractory acute GVHD in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. It is not known if Jakafi XR is safe or effective in children for the treatment of MF or PV. Jakafi XR and the Jakafi XR logo are trademarks of Incyte.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Incyte Corp.’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Just reported
From Incyte Corp.'s results release of October 29, 2026; its quarterly report has since been filed.
Actual
$1.56B
+14% y/y
-7.0% q/q
Guided
—
No guide given
Actual
-$3.86
Guided
—
No guide given
Actual
-$708.4M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Call summaries are part of Pro
A two-minute read of every Incyte Corp. earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.